drugset / Trial / NCT02195687

BOTOX® in the Treatment of Crow's Feet Lines in China

NCT02195687 ↗

Phase 3 Completed 417 enrolled Allergan
RandomizedParallel-groupTriple-blindTreatment

Summary

This study will evaluate the safety and efficacy of BOTOX® (botulinum toxin Type A) compared with placebo in patients with moderate to severe crow's feet lines (lateral canthal lines).

Timeline

Start
2014-09
Primary completion
2015-02
Completion
2015-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum toxin type A Protein / enzyme biologic 24 iu Other

Indications